BNP Paribas Financial Markets Buys 10,774 Shares of Haemonetics Co. (NYSE:HAE)

BNP Paribas Financial Markets raised its stake in shares of Haemonetics Co. (NYSE:HAE) by 174.5% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 16,949 shares of the medical instruments supplier’s stock after acquiring an additional 10,774 shares during the quarter. BNP Paribas Financial Markets’ holdings in Haemonetics were worth $1,362,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of HAE. Royce & Associates LP increased its stake in shares of Haemonetics by 2.6% in the third quarter. Royce & Associates LP now owns 1,210,546 shares of the medical instruments supplier’s stock worth $97,304,000 after purchasing an additional 30,868 shares during the period. Thrivent Financial for Lutherans increased its stake in shares of Haemonetics by 29.5% in the third quarter. Thrivent Financial for Lutherans now owns 1,100,183 shares of the medical instruments supplier’s stock worth $88,433,000 after purchasing an additional 250,833 shares during the period. Dimensional Fund Advisors LP increased its stake in shares of Haemonetics by 6.3% in the second quarter. Dimensional Fund Advisors LP now owns 978,735 shares of the medical instruments supplier’s stock worth $80,972,000 after purchasing an additional 57,665 shares during the period. Westfield Capital Management Co. LP increased its stake in shares of Haemonetics by 10.9% in the third quarter. Westfield Capital Management Co. LP now owns 823,663 shares of the medical instruments supplier’s stock worth $66,206,000 after purchasing an additional 80,783 shares during the period. Finally, Boston Trust Walden Corp increased its stake in shares of Haemonetics by 13.8% in the third quarter. Boston Trust Walden Corp now owns 809,608 shares of the medical instruments supplier’s stock worth $65,076,000 after purchasing an additional 98,019 shares during the period. 99.67% of the stock is currently owned by institutional investors.

Haemonetics Stock Up 0.6 %

Shares of HAE opened at $81.19 on Monday. The company has a market capitalization of $4.08 billion, a P/E ratio of 33.69, a PEG ratio of 1.30 and a beta of 0.38. The company has a debt-to-equity ratio of 1.39, a current ratio of 3.49 and a quick ratio of 2.09. Haemonetics Co. has a one year low of $70.25 and a one year high of $97.97. The business’s 50 day simple moving average is $80.68 and its 200-day simple moving average is $81.69.

Haemonetics (NYSE:HAE) last announced its earnings results on Thursday, November 7th. The medical instruments supplier reported $1.12 EPS for the quarter, topping the consensus estimate of $1.09 by $0.03. The business had revenue of $345.50 million for the quarter, compared to the consensus estimate of $342.57 million. Haemonetics had a return on equity of 22.67% and a net margin of 9.10%. Haemonetics’s revenue was up 8.6% compared to the same quarter last year. During the same period in the previous year, the business earned $0.99 EPS. As a group, sell-side analysts predict that Haemonetics Co. will post 4.59 EPS for the current fiscal year.

Analysts Set New Price Targets

HAE has been the topic of a number of recent analyst reports. Barrington Research reiterated an “outperform” rating and issued a $108.00 price objective on shares of Haemonetics in a research note on Wednesday, December 4th. JPMorgan Chase & Co. initiated coverage on Haemonetics in a research note on Friday. They set an “overweight” rating and a $116.00 price target on the stock. Citigroup lowered their price target on Haemonetics from $94.00 to $85.00 and set a “neutral” rating on the stock in a research note on Thursday, August 22nd. Raymond James upgraded Haemonetics from an “outperform” rating to a “strong-buy” rating and set a $120.00 price target on the stock in a research note on Friday, November 8th. Finally, BTIG Research initiated coverage on Haemonetics in a research note on Tuesday, September 10th. They set a “buy” rating and a $112.00 price target on the stock. Three investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $108.78.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.